DAX23.931 -0,3%ESt505.356 -0,2%Top 10 Crypto14,10 +1,4%Dow42.305 +0,1%Nas19.243 +0,7%Bitcoin92.175 -0,3%Euro1,1425 -0,1%Öl64,71 -0,6%Gold3.356 -0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 RENK RENK73 HENSOLDT HAG000 NVIDIA 918422 BioNTech (ADRs) A2PSR2 Gerresheimer A0LD6E Tesla A1CX3T Siemens Energy ENER6Y BYD A0M4W9 Lufthansa 823212 Bayer BAY001 thyssenkrupp 750000 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX fester erwartet -- Asiens Börsen in Grün -- Weißes Haus stellt Telefonat von Trump und Xi in Aussicht -- Rheinmetall ersetzt Kering im EuroStoxx 50
Top News
Rheinmetall-Aktie gesucht: Rheinmetall ersetzt Kering im EuroStoxx 50 - Auch RENK- und HENSOLDT-Aktie höher Rheinmetall-Aktie gesucht: Rheinmetall ersetzt Kering im EuroStoxx 50 - Auch RENK- und HENSOLDT-Aktie höher
Darum gibt der Euro einen Teil der Gewinne vom Montag wieder ab Darum gibt der Euro einen Teil der Gewinne vom Montag wieder ab
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Transgene Aktie

Handeln
Transgene Aktien-Sparplan
0,9400 EUR -0,0500 EUR -5,05 %
STU
0,9820 EUR +0,3100 EUR +46,13 %
PAR
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.88,66 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN913048

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINFR0005175080

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolTRGNF

Transgene Aktien News

DatumMeistgelesen
GlobeNewswireTransgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025
GlobeNewswireTransgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
GlobeNewswireTransgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
Wer­bungTransgene-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswireTransgene's Combined General Meeting of May 15, 2025
GlobeNewswireTransgene Provides Business and Financial Update for Q1 2025
GlobeNewswireAvailability of Preparatory Documents for the Combined General Meeting of May 15, 2025
GlobeNewswireTransgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025
GlobeNewswireAvailability of Transgene’s 2024 Universal Registration Document (URD)
GlobeNewswireTransgene Appoints Chief Technical Officer (CTO) to Power Future Innovations
GlobeNewswireTransgene to Participate in Upcoming Investor Meetings
GlobeNewswireTransgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
GlobeNewswireTransgene to Participate in the Biomed Forum Investor Conference
GlobeNewswireTransgene Announces Financial Calendar for 2025
GlobeNewswireBalance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024
GlobeNewswireTransgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
GlobeNewswireTransgene Reports Business, Pipeline and Financial Update for Q3 2024
GlobeNewswireTransgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
GlobeNewswireTransgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
GlobeNewswireTransgene to Present a Poster on Updated Data for TG4050 at SITC 2024
GlobeNewswireTransgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
GlobeNewswireAvailability of Transgene’s Half-Year Financial Report as of June 30, 2024
GlobeNewswire2024 Half-Year Financial Report
GlobeNewswireTransgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
GlobeNewswireTransgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
GlobeNewswireTransgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
GlobeNewswireTransgene to Participate in HTID Conference and Investor Access Forum in Paris
GlobeNewswireTransgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC
GlobeNewswireTransgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
GlobeNewswireBalance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2024
GlobeNewswireTransgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
GlobeNewswireTransgene’s Combined General Meeting of May 15, 2024
GlobeNewswireTransgene provides business and financial update for Q1 2024
GlobeNewswireAvailability of Preparatory Documents for the Combined General Meeting of May 15, 2024
GlobeNewswireAvailability of Transgene's 2023 Universal Registration Document
GlobeNewswireTransgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
GlobeNewswireTransgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
GlobeNewswireTransgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
GlobeNewswireTransgene Announces Upcoming Investor Meetings
GlobeNewswireTransgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
GlobeNewswireTransgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Wer­bung

Transgene News

Transgene News: auf dieser Seite finden Sie alle Transgene News und Nachrichten zur Transgene Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Transgene News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Transgene News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.